English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

> It is a capital mistake to theorise before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts. > > —Sir Arthur Ignatius Conan Doyle, 1892, The Adventures of Sherlock Holmes , Sherlock Holmes in "A Scandal in Bohemia"See related article, p 1877Ongoing discussions address the optimum dose of r-tPA (recombinant tissue plasminogen activator). Although in most countries in the world, the so-called standard dose of 0.9 mg/kg bodyweight is approved and used (based on numerous randomized controlled trials and joint and meta-analyses), in Japan and some other Asian countries, a low dose of 0.6 mg/kg bodyweight has been proposed or approved. Besides cost issues, the original rationale for the low dose was derived from the fear that Asians are a more bleeding-prone ethnic group and was tested because of safety concerns. On the contrary, the value of having 1 drug at 1 dose for an emergency situation is helpful because it is still a challenge to establish only that worldwide.After a single-arm nonrandomized study in 103 patients in J-ACT 11 (Japan Alteplase Clinical Trial), the dose of 0.6 mg/kg was approved in Japan. Efficacy and safety of this lower-dose thrombolytic therapy were confirmed by postmarketing surveys and registries in Japan, that is, J-ACT 22 (58 patients), J-MARS (Japan Postmarketing Alteplase Registration Study3; 7492 patients; 4944 with 3-month outcomes), and SAMURAI (Stroke Acute Management With Urgent Risk-Factor, Assessment Improvement Study)4 (600 patients). All these nonrandomized studies suggested with a low data quality (because of trial design) that intravenous thrombolysis with a 0.6 mg/kg dose achieved numerically similar outcomes and safety end points as comparable data sets from the large randomized controlled clinical trials.There is nothing like first hand evidence.5 About 1 year ago, Anderson …

Another Enchantment From ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study)